Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

419
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
419
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

466
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
466
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

54
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
54
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gamma knife radiosurgery for high grade glial neoplasms: a Canadian experience.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2013
Same author

Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2013
Same author

Surgical practice of UK gynaecological oncologists in the treatment of primary advanced epithelial ovarian cancer (PAEOC): a questionnaire survey.

Gynecologic oncology·2013
Same author

Gamma knife in the treatment of pituitary adenomas: results of a single center.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2013
Same author

Gamma knife radiosurgery for large vestibular schwannomas: a Canadian experience.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2013
Same author

Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study.

British journal of cancer·2013

Related Experiment Video

Updated: Feb 28, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.9K

"Fast Track" Development and Approval Process for Heart Failure Therapeutics.

L Papadimitriou1, J Butler1

  • 1Stony Brook University, Cardiology Division, Stony Brook, New York, USA.

Clinical Pharmacology and Therapeutics
|June 22, 2017
PubMed
Summary

Heart failure (HF) is a global health crisis. Improving the drug development and approval process can expedite access to life-saving treatments for heart failure patients, ensuring safety and better outcomes.

More Related Videos

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

10.9K
Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening
10:39

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Published on: April 15, 2017

13.7K

Related Experiment Videos

Last Updated: Feb 28, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.9K
Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

10.9K
Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening
10:39

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Published on: April 15, 2017

13.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Regulatory Science

Background:

  • Heart failure (HF) presents a significant global health challenge, characterized by high mortality and morbidity rates.
  • Timely access to effective therapeutic interventions is crucial for managing heart failure patients.
  • Existing regulatory frameworks aim to balance expedited drug approval with patient safety.

Purpose of the Study:

  • To explore strategies for enhancing and expediting the drug development and approval process for heart failure therapies.
  • To identify potential improvements in regulatory pathways that could accelerate patient access to novel treatments.
  • To maintain patient safety standards while streamlining the introduction of new heart failure medications.

Main Methods:

  • Review of current FDA drug approval mechanisms for cardiovascular diseases.
  • Analysis of regulatory pathways for expediting therapeutic regimens.
  • Examination of strategies to improve patient outcomes in heart failure management.

Main Results:

  • The US Food and Drug Administration (FDA) has implemented processes to facilitate drug approval.
  • Further guidance and enhancements to these processes show potential for greater efficiency.
  • Optimizing the drug development pipeline can lead to earlier patient access to critical treatments.

Conclusions:

  • Expediting the drug development and approval process for heart failure is essential for improving patient outcomes.
  • Enhancing existing FDA mechanisms can accelerate the availability of life-saving therapies.
  • Balancing speed with rigorous safety protocols is paramount in heart failure drug regulation.